DNA-targeted radioimmunotherapy

Funded Activity Summary

Radioimmunotherapy is an experimental method of cancer treatment, involving the use of radioactive isotopes, which are targeted to tumour cells using specific molecules as carriers. These carriers are known as anti-tumour antibodies, and they bind specifically to tumour cells. Recent advances in molecular biology and in the understanding of the nature of tumour cells has resulted in the development of improved anti-tumour antibodies, and such improvements can be expected to continue. However, this project is concerned not with the tumour targeting aspect of radioimmunotherapy, but rather with the payload or cytotoxic mechanism, in which the radiation damage is focused on the DNA of the cell. In summary, the project explores a new approach in cancer radioimmunotherapy. This approach will be evaluated firstly in cultures of tumour cells and then in mice bearing transplanted tumours. If successful this project will result in the development of a new cell kill technology that can be combined with different anti-tumour antibodies.

Funded Activity Details

Start Date: 01-01-2002

End Date: 01-01-2004

Funding Scheme: NHMRC Project Grants

Funding Amount: $391,650.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Radiotherapy And Nuclear Medicine

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Auger electron-emitting isotopes | DNA strand breakage | EGF receptor mediated endocytosis | metastases | minimal residual disease | minor groove binding DNA ligands | oncology | radioimmunotherapy

Related Links